We examined the association of three established single nucleotide polymorphisms, IVS1-397T>C, IVS1-351A>G, and +261G>C, in the ESR1 gene with the prevalence and severity of coronary atherosclerosis in a southern Brazilian population of European ancestry. Three hundred and forty-one subjects (127 women and 214 men) with coronary artery disease (CAD) were classified as having significant disease (CAD+ patient group) when they showed 60% or more luminal stenosis in at least one coronary artery or major branch segment at angiography; patients with 10% or less luminal stenosis were considered to have minimal CAD (CAD-patient group). The control sample consisted of 142 subjects (79 women and 63 men) without significant disease, in whom coronary angiography to rule out the presence of asymptomatic CAD was not performed. The polymorphisms were investigated by polymerase chain reaction followed by restriction analyses. In the male sample, the +261G>C*C allele was more frequent in CAD+ than CAD-subjects (8 versus 1%, P = 0.024). Homozygosity for the C allele of the IVS1-397T>C polymorphism was also significantly associated with increased CAD severity (OR: 2.99; 95% CI = 1.35-6.63; P = 0.007). In agreement with previous findings, these results suggest that the IVS1-397T>C*C allele was associated with CAD severity independent of gender, whereas the association of the +261G>C variant with CAD was observed in males only. The relation between ESR1 variation and CAD may influence clinical decisions such as the use of hormone therapy, and additionally will be helpful to identify the genetic susceptibility determinants of cardiovascular disease development.
Introduction
The cardioprotective effects of estrogen are known and may be mediated by systemic effects on lipid profile (1), coagulation and/ or fibrinolysis (2) . However, the direct actions of estrogen on blood vessels might contribute considerably to the cardioprotective effects of this hormone; estrogen increases vasodilatation, accelerates endothelial cell growth, and inhibits the migration and proliferation of smooth muscle cells in vitro and the response of blood vessels to injury and development of atherosclerosis (2) . Estrogen may also be considered to have an anti-inflammatory action by decreasing several inflammation markers. Nevertheless, some studies have demonstrated a rise in C-reactive protein levels after initiation of oral estrogen plus progesterone replacement therapy in postmenopausal women (3, 4) .
Ohlsson et al. (5) and Hodgin et al. (6) reported that the cholesterol-lowering effect of 17ß-estradiol in mice depends on the presence of estrogen receptor 1 (ESR1). Chen et al. (7) demonstrated that this receptor mediates the nongenomic activation of endothelial nitric oxide synthase.
Three polymorphisms have been extensively studied in the ESR1 gene, two in the first intron IVS1-397T>C (rs2234693) and IVS1-351A>G (rs9340799), and a silent mutation in exon 1, +261G>C (rs746432). These variants were initially associated with onset of menopause (8) , bone density (9,10), hypertension (11) , body mass index (12) , cardiovascular disease, and intermediate cardiovascular markers (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . More recently a TA dinucleotide repeat polymorphism has been described and reported to be associated with the severity of cardiovascular disease (23, 24) . Although several studies on association with cardiovascular disease have been performed, inconsistent results have been obtained. How and to what extent polymorphisms in the ESR1 gene might function as genetic markers of vascular pathology is also not known. Therefore, repeating the studies of the association of ESR1 polymorphisms with cardiovascular disease in diverse settings and populations is very important to assess if this genetic variability can influence the susceptibility to cardiovascular disease.
In the present study, we examined the association of three established single nucleotide polymorphisms (SNPs), IVS1-397T>C, IVS1-351A>G, and +261G>C in the ESR1 gene with the prevalence and severity of coronary atherosclerosis in a southern Brazilian sample of European ancestry.
Subjects and Methods

Patients and controls
Coronary artery disease sample. The study was conducted on 341 individuals (127 women and 214 men) of European descent, ascertained by morphological characteristics as previously described (25) , who required coronary angiography due to symptoms related to coronary artery disease (CAD). These patients were of unrestricted age and were contacted at the Hospital de Clínicas de Porto Alegre (HCPA). Informed consent to provide a blood sample for DNA extraction to be used in studies approved by the Hospital Ethics Committee was obtained from each subject included in the sample. A questionnaire which included details on lifestyle variables such as smoking, physical activity, and anthropometric measures was completed by the subjects. Subjects were classified for smoking status as never smokers, and smokers (past or current smoking). Patients were classified as having significant disease (CAD+ patient group) if they showed 60% or more luminal stenosis in at least one coronary artery or major branch segment at angiography. Patients with 10% or less luminal stenosis were considered to have minimal CAD (CAD-patient group) and patients with an occlusion between 11 and 59% were considered to have intermediate CAD and were not included in the severity analyses.
Control sample. The control sample consisted of 142 subjects (79 women and 63 men) of European descent. As done for the patients, the ethnicity of these individuals was classified in terms of physical characteristics. The subjects included in this sample were randomly selected from two clinical centers at the Federal University of Rio Grande do Sul among those who came from several city health centers for free routine blood determinations. Only those without significant disease were included. In these latter subjects, it was unethical to perform coronary angiography to rule out the presence of asymptomatic CAD. A question-naire which included details on drug intake and lifestyle variables such as smoking, physical activity, alcohol consumption, oral contraceptive use, menopause status, and anthropometric measures was completed. For smoking status, subjects were classified as never smokers and current smokers (ex-smokers were excluded). All individuals gave written informed consent prior to the investigation. Exclusion criteria were pregnancy, secondary hyperlipidemia due to renal, hepatic or thyroid disease, and diabetes or fasting blood glucose levels higher than 6.9 mmol/L.
All subjects were studied in the morning after a 12-h fast. Weight was measured in subjects without shoes and wearing light clothing. Body height was determined without shoes, heels together, with the back to the wall. Body mass index was calculated as weight/height 2 (kg/m 2 ). Waist circumference was measured at the smallest horizontal circumference between the 12th rib and the iliac crest.
DNA analyses
Genomic DNA was extracted from peripheral blood leukocytes by the method of Lahiri and Nurnberger Jr. (26) . The ESR1 SNPs (IVS1-397T>C, IVS1-351A>G, and +261G>C) were amplified by the polymerase chain reaction using the same conditions and oligonucleotide primers as previously described (10, 27, 28) . The amplification products were subsequently digested with restriction enzymes under conditions recommended by the manufacturer: PvuII (IVS1-397T>C), XbaI (IVS1-351A>G), and BstUI (+261G>C). The genotypes were determined after agarose gel electrophoresis with ethidium bromide, using a 50-bp ladder to score the band sizes.
Biochemical analyses
Blood samples were collected from patients after a 12-h fast. Total cholesterol, HDL-cholesterol, tryglyceride, and glucose levels were determined by standard methods using commercial kits. LDL-cholesterol was calculated according to the Friedewald formula (29) . The lipid levels of patients and controls were analyzed by similar standard methods at two clinical centers of the Federal University of Rio Grande do Sul during the period from 2000 to 2001 on the same day of sample collection.
Statistical analyses
Allele frequencies at the individual loci were estimated by counting. The agreement of genotype frequencies with Hardy-Weinberg equilibrium expectations was tested using the chi-square test. The PEPI statistical program version 4.0 (30) was used to compare the frequencies among groups, adjusted residuals, and the power of the test. The groups were compared by the Student ttest or one-way analysis of variance using the Graph Pad InStat software version 2.04a (Graph Pad Software, San Diego, CA, USA). Multiple logistic regression was performed using the SPSS statistical package (SPSS ® for Windows ™ , version 8.0). The maximum likelihood estimate of haplotype frequencies was calculated from multisite marker data using the Multiple Locus Haplotype Analysis software, version 2.0 (31-33). Linkage disequilibrium was tested by a χ 2 goodness of fit test using the Arlequin program, version 2.000 (34) . D' values, the relative magnitude of linkage disequilibrium, were calculated as described previously (35) .
Results
The characteristics of patients and controls are reported in Table 1 . CAD+ women were older than controls and CAD-women (P < 0.001). The prevalence of hypertension was also higher in CAD+ women than in the other groups (P < 0.001). CAD+ men were also older than controls and CAD-men (P = 0.019). Mean total cholesterol and LDL- Unadjusted data and continuous data are reported as mean ± SD. T-chol = total cholesterol; HDL-C = HDL-cholesterol; LDL-C = LDL-cholesterol; TG = triglycerides; BMI = body mass index. CAD-= minimal coronary artery disease; CAD+ = coronary artery disease. Data were analyzed by one-way analysis of variance followed by the Tukey post hoc test when necessary for continuous variables and by the chi-square test followed by adjusted residual analysis for categorical values. a-f Tukey HSD test, P < 0.01. g Adjusted residual P < 0.01. h Adjusted residual P < 0.001. Women Men cholesterol levels were higher in CAD+ men than in CAD-men. The prevalence of smokers and ex-smokers, as well as hypertension, was higher in CAD+ men. Allele and genotype frequencies for the ESR1 variants in all subsamples are shown in Table 2 stratified by gender. The genotype frequencies observed for all polymorphisms studied did not differ significantly from those expected under Hardy-Weinberg equilibrium. Regarding the +261G>C polymorphism only one C/C homozygote was detected in the samples studied; therefore, for statistical analysis purposes this subject was assigned to the G/C group. No statistically significant difference was detected in allele or genotype (Table 2 ) frequencies among the three female groups. But in the male sample, the +261G>C*C allele was more frequent in CAD+ than CAD-subjects (8 versus 1%, P = 0.024). The power of the test was 80%.
The effects of the ESR1 genotypes on CAD severity were also evaluated using the percentage of luminal stenosis as the dependent variable (CAD-≤10% and CAD+ ≥60%) in a multiple logistic regression analysis. In the whole sample, the variables that remained statistically associated with CAD severity are shown in Table 3 . After controlling for age, gender, hypercholesterolemia and smoking, homozygosity for the IVS1-397T>C*C allele was found to be significantly associated with increased CAD severity (OR: 2.99; 95% CI = 1.35-6.63; P = 0.007).
Seven ESR1 haplotypes were detected in the investigated sample (data not shown). Table 4 ). ESR1 genotypes and haplotypes were not associated with lipid levels in the present study (data not shown).
Discussion
Recently two large, well-designed and well-implemented studies were published with apparent contradictory results in rela- Table 3 . Multiple logistic regression model and prediction of variables for coronary atherosclerosis disease severity using the percentage of luminal stenosis as the dependent variable [CAD-≤10% (N = 112) and CAD+ ≥60% (N = 210)]. CAD-= minimal coronary artery disease; CAD+ = coronary artery disease. OR = odds ratio. have an increased risk of myocardial infarction and ischemic heart disease whereas an absence of this association in men was reported in that study. As pointed out by Newton-Cheh and O'Donnell (36), there are some differences between the two studies, but a review of the available criteria points to no firm conclusion about which of the two studies should be regarded as the most valid. Several other studies also showed conflicting results. A beneficial effect of the IVS1-397T>C*C allele has been reported in some studies. The presence of the IVS1-397T>C*C allele was protective against the risk of in-stent restenosis (18) ; postmenopausal women on hormone replacement therapy, homozygous for the C allele at the IVS1-397T>C site, showed less progression in atherosclerosis severity scores (22) . However, negative effects of the same allele have also been described by others. Nordström et al. (17) showed that the IVS1-397T>C*C allele was associated with risk of aortic valve sclerosis and coronary atherosclerosis at angiography in women. Evidence that the IVS1-397T>C site may modify coronary reactivity and LDL oxidation in healthy young men has also been reported (21) . In that investigation adenosine-stimulated blood flow values were lower in subjects with the C/C genotype at the IVS1-397T>C site than in subjects with other genotypes, and plasma levels of oxidized LDL were on average higher in C/C homozygous subjects than in subjects with C/T and T/T genotypes (21). Lehtimäki et al. (15) reported that the IVS1-397T>C*C allele was a risk factor for men aged 53 years or over, who have on average a larger area of complicated lesions. The data for the Brazilian sample investigated here are in agreement with these findings. The IVS1-397T>C*C allele was associated with CAD severity, but this effect was not gender specific, because IVS1-397T>C by gender interaction was not a significant variable in the logistic regression model. A 6% frequency of reduction of the +261G>C*G -IVS1397T>C*T -IVS1-351A>G*A haplotype was detected in CAD+ subjects when compared to the CAD-and control samples (Table 4) ; this observation probably reflects the increased frequency of the IVS1-397T>C*C allele in CAD+ subjects. These results are consistent with those reported by Shearman et al. (19) for males in the Framingham Heart Study.
IVS1-397T>C
In the present study, an effect of the +261G>C was also detected in the CAD sample, but restricted to males only. We have no explanation for this finding, but the differences in hormone dynamics between men and postmenopausal women are well known, and could account for the differences in association studies (20) . The functional implications of the IVS1-397T>C, IVS1-351A>G and +261G>C polymorphisms have not been fully elucidated, but it has been speculated that genetic variants of ESR1 modify the expression or affinity of this receptor by estrogen. The +261G>C polymorphism is a silent mutation, the wild sequence (+261G>C*G allele) codes least frequently for alanine in humans (7.1% of cases) and the silently mutated codon (+261G>C*C allele) codes most frequently (29.5% of cases) (11) . This might cause a modification of expression, but this hypothesis needs confirmation by expression studies. Herrington et al. (14) showed that IVS1-397T>C*T allele eliminates a functional binding site for the transcription factor Bmyb, which suggests that the presence of this allele may result in lower ESR1 transcription. Moreover, these polymorphisms might only be co-segregating in linkage disequilibrium with a truly functional but so far unknown sequence variation elsewhere in the ESR1 gene. The long alleles of the TA repeat polymorphism in the promoter of the ESR1 gene have been associated with impaired coronary function and are in linkage disequilibrium with the variants investigated here, but other functional SNPs cannot be ruled out (23, 24) .
In addition to the influence of estrogen on several factors involved in cardiovascular disease, such as lipid metabolism, coagulation and/or fibrinolysis, this hormone may be modifying the expression of various genes. Therefore, different polymorphisms may possibly exhibit association with different cardiovascular markers and also in opposite directions. According to Newton-Cheh and O'Donnell (36), "For both viewers and participants, the race for discoveries from genomic medicine will likely be a marathon, not a sprint", but the better identification of the relation between genomic variation and cardiovascular function may influence clinical decisions such as the use of hormone therapy for postmenopausal women and additionally will be helpful to identify the genetic susceptibility determinants of cardiovascular disease development.
